Condition: Intracranial Aneurysm · Sponsor: Medtronic Neurovascular Clinical Affairs
The purpose of the Pipeline™ Vantage Embolization Device with Shield Technology™ Post Approval Study (PAS) ("Pipeline™ Vantage PAS") is to collect safety and effectiveness data in patients undergoing treatment for intracranial aneurysms (IA) using the Pipeline™ Vantage Embolization Device with Shield Technology™ ("Pipeline™ Vantage Device") in a post approval setting.
This description comes directly from the study's public registry record.
Medtronic Neurovascular Clinical Affairs · 949-837-3700 · rs.vantagepas@medtronic.com
Always discuss trial participation with your own doctor first.
| Baptist Medical Center Jacksonville | Jacksonville, Florida, United States | Recruiting |
| Wellstar Research Institute | Marietta, Georgia, United States | Recruiting |
| Ascension St. Vincent Hospital Indianapolis Goodman Campbell Brain and Spine | Carmel, Indiana, United States | Recruiting |
| University of Iowa Hospitals and Clinics | Iowa City, Iowa, United States | Recruiting |
| McLaren Healthcare | Flint, Michigan, United States | Recruiting |
| Prisma Health | Greenville, South Carolina, United States | Recruiting |
| Semmes Murphey Clinic/Semmes Murphy Foundation | Memphis, Tennessee, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06604884